Evaluating the Durability & Biomarkers of Tolerance & Exploring Delivery Systems to Drive Antigen-Specific Immune Tolerance Approaches to Achieve Clinical Efficacy
The 10th Antigen-Specific Immune Tolerance Summit returns at a defining moment for the field. With Diamyd Medical generating pivotal Phase III data, COUR Pharmaceuticals reporting clinical findings from treated patients, and companies including Bonsai Biotherapeutics and Parvus Therapeutics advancing novel therapeutic approaches, antigen-specific immune tolerance is entering a critical phase of clinical validation.
As programs mature, the focus is shifting from demonstrating biological activity to proving durable clinical efficacy, defining meaningful biomarkers of tolerance, and generating the evidence needed to secure regulatory approval and attract investment.
Designed to address these challenges head-on, this year's meeting will explore how the community can translate scientific promise into clinical success. As the only industry-led meeting dedicated exclusively to antigen-specific immune tolerance, the summit brings together researchers, clinicians, biopharma leaders, investors, and key opinion leaders driving progress across autoimmune and allergy.
Don't miss the 10th anniversary summit where the future of immune tolerance will be debated, challenged, and defined.
-
It is truly the annual meeting in the ASIT field, bringing together a community dedicated to sharing knowledge, exchanging insights, and celebrating the advances shaping the field.
Chief Executive Officer, Bonsai Biotherapeutics
-
As antigen-specific tolerance rapidly transitions from concept to clinic, this summit stands out as a unique forum bridging immunology, bioengineering, and therapeutic development.
Instructor, Division of Immunology & Rheumatology, Stanford University
Co-Founder & Scientific Advisor, EBVio
-
The whole program was very informative. The collegial spirit and sharing of information was very refreshing, with everyone interested in seeing the field succeed and recognizing that success for one was a success for all.
Vice President Corporate Strategy, GSK
-
The Antigen-Specific Immune Tolerance Summit continues to succeed, thanks to engaging conference topics and active interest from participants. This year's event was another enjoyable and rewarding experience.
Professor, University of Basel
World Immune Tolerance Week
For the very first time, the 10th Antigen-Specific Immune Tolerance Summit is becoming part of World Immune Tolerance Week alongside the 9th Treg-Directed Therapies Summit and the 2nd Immune Resetting: B-Cell Mediated & Beyond Summit to bring together the full autoimmune and immunology disease community. While each summit retains its own scientific focus, expert speaker faculty, and community, attendees will gain access to all three meetings, enabling cross-disciplinary learning, richer networking, and collaboration across antigen-specific therapies, Treg approaches, B-cell modulation, and broader immune resetting strategies.
Advancing Transformative Therapies to Reset Autoimmune Diseases
Expand the Application of Treg Therapies into a Clinical Reality
Accelerating Curative Therapies for Autoimmune Diseases
Explore the Full Event Guide
- Gain a first look at the 2027 ASIT priorities shaping the future of immune tolerance and identify where you fit within the evolving landscape
- Discover dedicated workshop sessions focused on biomarkers of tolerance, pre-clinical models, and translational development
- Look forward to a panel dedicated to investment readiness to help de-risk and accelerate therapeutic development
- Maximize your on-site experience and connect with a broad network of autoimmune and immunology leaders as part of World Immune Tolerance Week
Official Partners
Attending Companies Include
Explore the Agenda
Hear the latest clinical developments from industry experts and gain exclusive insights from the packed agenda, interactive roundtables, and panel discussions.
Partner with the World Immune Tolerance Week
Position yourself alongside other leading solution providers to ensure your brand is at the heart immunology and autoimmune disease advancements.
Join a Community of Immunology Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during the dedicated networking sessions.